HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Supplement AER Under-Reporting Marks Tip Of Compliance Iceberg – FDA

This article was originally published in The Tan Sheet

Executive Summary

FDA’s dietary supplement program chief raised eyebrows at a botanical products conference citing low estimates on rates of compliance with the good manufacturing practices final rule and the new dietary ingredient notification requirements, as well as adverse event reporting.

You may also be interested in...



Medical Association's Diagnosis Of US Supplement Market Has Industry Asking For Second Opinion

AMA decides “to call for more stringent federal regulation of supplements—including increased oversight of manufacturing, marketing, product labeling, and adverse event reporting.” But NPA CEO Daniel Fabricant says supplements account for a fraction of the problems linked to drugs approved for sale in the US. "We don’t have a vitamin C crisis in America, we do have an opioid crisis."

Durbin Requests GAO Inquiry On Supplement Adverse Event Reports

Sen. Durbin says it is unclear how FDA’s adverse event reporting system works to protect consumer safety and asks GAO to investigate the agency’s collection and analysis of dietary supplement AERs.

FDA Says Supplement Adverse Event Under-Reporting Should Feed Growth

FDA published a how-to guide to push dietary supplement firms toward tighter compliance with the requirement to submit serious adverse event reports to the agency.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM013195

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel